Treatment of control siRNA with the ERK1/2 kinase inhibitor (SCH772984) resulted in a slight increase in the extent of TfnR recycling in both HCC4017 NSCLC cells and normal ARPE-19 cells (S1 Fig). Here, BDP1 is linked to non-small cell lung carcinoma.